Secondary Analysis of Landmark TAILORx Results, Published in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® Test to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision

Media coverage

• Title	Secondary Analysis of Landmark TAILORx Results, Published in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® Test to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision
  Media name/outlet	PR Newswire European (Top News)
  Country/Territory	United Kingdom
  Date	4/06/19
  Persons	Joseph Sparano